Article
Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study.
Clinical pharmacokinetics - 1 Jul 2016
Dickinson Laura, Amin Janaki, Else Laura, Boffito Marta, Egan Deirdre, Owen Andrew, Khoo Saye, Back David, Orrell Catherine, Clarke Amanda, Losso Marcelo, Phanuphak Praphan, Carey Dianne, Cooper David A, Emery Sean, Puls Rebekah
Abstract excerpt
BACKGROUND: ENCORE1 demonstrated non-inferiority of daily efavirenz 400 mg (EFV400) versus 600 mg (EFV600) to 96 weeks in treatment-naïve, HIV-infected adults but concerns regarding lower EFV400 concentrations remained. Therefore, relationships between EFV pharmacokinetics (PK) and key genetic polymorphisms with 96-week efficacy and safety were investigated. METHODS: Relationships between EFV PK parameters and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.